Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cohance Lifesciences's Total Assets for the quarter that ended in Jun. 2026 was ₹0 Mil.
Warning Sign:
If a company builds assets at 30.8% a year, faster than its revenue growth rate of 11.8% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Cohance Lifesciences's average Total Assets Growth Rate was 96.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 53.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 30.80% per year.
During the past 8 years, Cohance Lifesciences's highest 3-Year average Total Assets Growth Rate was 53.90%. The lowest was 3.70%. And the median was 19.40%.
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Cohance Lifesciences's Asset Turnover for the quarter that ended in Jun. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Cohance Lifesciences Total Assets Related Terms
Cohance Lifesciences Total Assets Historical Data
* Premium members only.
The historical data trend for Cohance Lifesciences's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Cohance Lifesciences's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cohance Lifesciences (BOM:543064) has a Total Assets of ₹0 Mil as of Jun. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Cohance Lifesciences and its competitors.
Is Cohance Lifesciences' Total Assets too high?
Cohance Lifesciences' current Total Assets is ₹0 Mil. Overall, Cohance Lifesciences has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cohance Lifesciences' Total Assets compare to ZTS?
Cohance Lifesciences' Total Assets of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Cohance Lifesciences and its competitors. Cohance Lifesciences's current Total Assets is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cohance Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Cohance Lifesciences (BOM:543064) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹644.50, compared to a current price of ₹462.60 — trading 28.2% below its estimated fair value. The current Total Assets is ₹0 Mil. Cohance Lifesciences' overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Cohance Lifesciences (BOM:543064), the current Total Assets is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cohance Lifesciences (BOM:543064) Overvalued in 2026?
Based on GuruFocus' analysis, Cohance Lifesciences stock appears to be undervalued.
The current stock price of ₹462.60 is trading 28.2% below its estimated GF Value™ of ₹644.50.
GuruFocus considers Cohance Lifesciences to be Modestly Undervalued.
Key valuation signals for BOM:543064:
Total Assets: ₹0 Mil
GF Value™: ₹644.50 vs. price of ₹462.60 (28.2% below fair value)
No single metric tells the full story. See the BOM:543064 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
88GF Score
Get the complete analysis for BOM:543064
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543064 has been successfully added to your 
